Processa Pharmaceuticals, Inc. — Cyborg Score 3/10
Challenged
Oncology Drugs
Strategic Profile
The company completed enrollment of 20 patients in its randomized Phase 2 study of NGC-Cap in advanced or metastatic breast cancer, with formal interim analysis expected in Q1 2026. Preliminary Phase 2 data show increased exposure to capecitabine metabolites with a safety profile comparable to capecitabine monotherapy.
Cyborg Score Rationale
Market cap of $7.29M as of April 2026 reflects a micro-cap clinical-stage company with limited financial resources. Wall Street forecasts show continued negative earnings through 2027 with no revenue generation expected. With only 12 employees, the company operates a lean pipeline with execution risk dependent on Phase 2 clinical outcomes.
Top Insights
Phase 2 NGC-Cap interim analysis completed in Q1 2026 will assess comparative safety/efficacy and guide decisions on dosage arms and sample size expansion.
Stock trading at $2.87 (April 2026) with 52-week range of $1.76–$19.63, reflecting extreme volatility and previous collapse from much higher levels.
Clinical-stage company forecasted to generate $0 revenue through 2029 per Wall Street consensus, with negative earnings trajectory.
Company presented at J.P. Morgan Healthcare Conference (January 2026), actively seeking investor and partnership discussions around NGC-Cap pipeline.
Named Competitors
Abraxane/albumin-bound paclitaxel — Breakthrough nanoparticle chemotherapy for advanced breast cancer
Kadcyla (trastuzumab emtansine) — HER2-targeted antibody-drug conjugate for breast cancer
Herceptin (trastuzumab) — Monoclonal antibody targeting HER2 in breast cancer
Recent Developments
(January 2026) Completed enrollment and dosing of 20 patients required for formal interim analysis in Phase 2 NGC-Cap breast cancer study
(December 2025) Provided Phase 2 clinical update for NGC-Cap showing preliminary positive exposure and safety data
(January 2026) Attended J.P. Morgan Healthcare Conference to discuss clinical pipeline and seek partnership opportunities
Open the full interactive Processa Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.